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Background: Acquired uniparental disomy (aUPD) can lead to homozygosity for tumor suppressor genes or
oncogenes. Our purpose is to determine the frequency and profile aUPD regions in serous ovarian cancer (SOC)
and investigated the association of aUPD with clinical features and patient outcomes.
Methods: We analyzed single nucleotide polymorphism (SNP) array-based genotyping data on 532 SOC specimens
from The Cancer Genome Atlas database to identify aUPD regions. Cox univariate regression and Cox multivariate
proportional hazards analyses were performed for survival analysis.
Results: We found that 94.7% of SOC samples harbored aUPD; the most common aUPD regions were in chromosomes
17q (76.7%), 17p (39.7%), and 13q (38.3%). In Cox univariate regression analysis, two independent regions of aUPD on
chromosome 17q (A and C), and whole-chromosome aUPD were associated with shorter overall survival (OS), and five
regions on chromosome 17q (A, D-G) and BRCA1 were associated with recurrence-free survival time. In Cox multivariable
proportional hazards analysis, whole-chromosome aUPD was associated with shorter OS. One region of aUPD on
chromosome 22q (B) was associated with unilateral disease. A statistically significant association was found between
aUPD at TP53 loci and homozygous mutation of TP53 (p < 0.0001).
Conclusions: aUPD is a common event and some recurrent loci are associated with a poor outcome for patients with
serous ovarian cancer.
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Ovarian cancer is the fifth most common cancer among
women, with an estimated 21,880 new cases per year in
the United States [1]. Ovarian cancer has the highest
mortality rate of female reproductive system cancers and
is the fourth leading cause of cancer-related death in
women, responsible for an estimated 13,850 deaths per
year in the United States [1]. The mortality rate for ovar-
ian cancer remains high because the disease is usually
diagnosed at an advanced stage when cure rates are low;
the 5-year survival rate for patients with advanced dis-
ease remains approximately 30% [2].
Approximately 90% of ovarian cancers are designated
epithelial ovarian cancers (EOCs) with the majority aris-
ing either from cells lining the fallopian tube or the* Correspondence: mtuna9@gmail.com
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unless otherwise stated.ovarian surface; the remaining 10% of ovarian cancers
are germ cell and stromal tumors [3,4]. Ovarian cancer
is a heterogeneous disease at the genetic level. The
most common subtype is serous carcinoma, which
comprises ~60% of EOCs [5]. Serous carcinoma can be
subdivided into high-grade (HG; grades 2 and 3) and low-
grade (LG; grade 1) with a strong association with patient
outcomes [2]. Most serous ovarian cancers are high grade
accounting for the great majority of deaths from ovarian
cancer. Molecular analysis has shown that LG and HG
serous carcinomas harbor distinct genetic events and do
not interconvert [6-9]. Therefore, LG and HG serous OCs
are now thought to be different diseases with distinct mo-
lecular characteristics and behavior [10-12].
The advent of high-density single nucleotide poly-
morphism (SNP) arrays combined with emerging analyt-
ical tools has made it possible to identify genome-wide
copy number changes and allele-specific alterations in
cancer. However, little is known about the contributionhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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UPD occurs when two homologous chromosomes, or seg-
ments of chromosomes, originate from the same parent
[14]. UPD can either be constitutional or acquired (aUPD)
during tumor initiation and progression. Acquired unipa-
rental disomy (aUPD), also known as copy neutral loss of
heterozygosity is a relatively common event in cancer
[13,15-19]. aUPD can occur in two different ways; loss of
one chromosome followed by duplication of the remaining
chromosome (with the homologous chromosomes
arising either maternally or paternally) leads to whole-
chromosome aUPD, whereas somatic recombination leads
to segmental aUPD. In both cases, copy number does not
change. aUPD has the potential to lead to homozygosity of
existing aberrations such as mutation, deletion, methyla-
tion, histone-modification, or imprinted genes. Therefore
aUPD could contribute to development and/or progression
of cancer by inactivating tumor suppressor genes or doub-
ling the copy number of oncogenic alleles.
Until now, aUPD has not been correlated with disease
outcome in large scale studies of ovarian cancer. There-
fore, the purpose of this study was to use a large sample
set to determine the frequency of aUPD, to identify re-
current aUPD regions, and to test whether the most fre-
quent aUPD regions are correlated with overall survival
(OS) and recurrence-free survival (RFS) in serous epithe-
lial ovarian cancer.
Materials and methods
Samples
We analyzed SNP array-based genotyping data from 532
tumor samples analyzed by The Cancer Genome Atlas
(TCGA) project [20].Tissue sample and clinical data
were retrieved from the TCGA Data Portal (http://tcga-
portal.nci.nih.gov/tcga-portal). Patient demographics are
summarized in Additional file 1: Table S1. The median
OS time was 28.5 months (range, 0.27 to 182.7 months).
RFS time was calculated from the date of diagnosis of
ovarian cancer to the date of recurrence or last follow-
up. OS time was calculated from the date of diagnosis of
ovarian cancer to the date of death or last follow-up.
Sample and clinical data were based on a November
2013 freeze from TCGA data portal. Recurrence data and
vital status were available for 532 patients (Additional
file 1: Table S1). Primary response to treatment, which
was defined as primary therapy outcome success; pro-
gressive disease, partial response, complete response and
stable disease was determined after primary surgery and
subsequent adjuvant chemotherapy. Platinum sensitivity
was defined as previously published [20]. The organ side
was defined as bilateral, if SOC occured in both ovaries,
and was defined as unilateral if SOC occured in only the
right or left ovary. The mutation status of genes was re-
trieved from the TCGA data portal [20].Genomic data and analysis
Genomic data sets (CEL files) were retrieved from the
TCGA data portal (http://tcga-portal.nci.nih.gov/tcga-
portal). In this study, we only included genomic data
from serous ovarian tumors.
Determination of aUPD
After quality control was performed on the data using
Genotyping Console software (Affymetrix), CHP files
were generated. The data that passed the quality control
process included 532 tumor specimens from TCGA.
Copy Number Analyser for GeneChip (CNAG) version
3.4 software (http://www.genome.umin.jp) with a hidden
Markov model algorithm [21] was used to identify aUPD
regions. The analysis of TCGA data was done by using
matching normal reference samples. In the aUPD ana-
lyses both genotype information and intensity were used.
Chromosome analysis suite (ChAS) (Affymetrix) was used
for validation of aUPD (Additional file 2: Figure S1). The
aUPD-score was calculated by counting the total number
of segmental aUPD regions (telomere and centromere) and
whole chromosome aUPD in each sample. If aUPD occurs
as a result of a single mitotic recombination, it is defined
as telomeric, and if aUPD occurs via two or more mitotic
recombination, it is defined as centromeric. The smallest
overlapping regions of aUPD were situated by comparing
aUPD endpoints (3′ and 5′). The May 2006 human gen-
ome browser (NCBI Build 36/hg18; http://genome.
ucsc.edu) was used for identification of gene localization.
Statistical analysis
Non-parametric Kruskal–Wallis or Wilcoxon Rank Sum
tests were used to compare the frequency of total, telo-
meric, centromeric, segmental, and whole-chromosome
aUPD between wild type and mutation, stage or grade
for aUPD regions associated with outcome of SOC. An
non-parametric Kruskal-Wallis test was used to evaluate
the correlation of aUPD regions and mutation of TP53,
double-strand break genes or homologous recombin-
ation genes (Additional file 3: Table S2) and frequency of
aUPD. This study complied with REMARK (reporting
recommendations for tumor-marker prognostic studies)
criteria [22]. TCGA samples were divided in two in-
dependent sets: set A consists of batchs#9-17; 270
samples and set B batchs#18-40; 262 samples. There
is no statistically difference between two groups in OS
time (p = 0.27), RFS time (p = 0.20) (Additional file 4:
Figure S2), age (p = 0.33), platinum status (p = 0.09), ana-
tomic side (p = 0.71) and total aUPD (p = 0.80), except
tumor stage (p = 4.8×10−4) and tumor grade (p = 1.4×10−5).
The significance tests between two independent sample
sets A and B were performed with the 2-sample student’s
t-test for age and total aUPD, log-rank test for OS and RFS
time, and with Chi-square’s test for platinum status,
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vival curves were used to plot RFS and OS probabilities for
groups with and without aUPD. The log-rank test was used
to test whether RFS and OS probability were significantly
different between the groups. Univariate cox proportional
hazards regression analysis (COXPH) was used to deter-
mine whether aUPD regions were associated with RFS
time and/or OS time. Multivariate Cox proportional haz-
ard model was performed to test differences in OS or RFS.
Multivariable analysis was constructed including the fol-
lowing variables: age, stage, grade, response to primary
therapy, platinum status, aUPD and mutation status of
PTEN, BRCA1, BRCA2, TP53, NF1 and RB1 genes and
UPD regions at chromosome 9q, 13q, 17p, 17q, 22q. A
goodness of fit chi-squared test was performed to evaluate
the association between aUPD regions at TP53 and homo-
zygous TP53 mutation. A chi-squared test was also used to
test the association between aUPD regions and unilateral
disease and resistance to therapy. A finding was declared
significant when the two-sided p-value was less than 0.05.
Multiple testing used the Benjamini-Hochberg procedureFigure 1 Genome-wide profiling of aUPD regions in 532 epithelial ov
tumor sample.[23] to control the false discovery rate (FDR) at less than
0.05. Statistical analyses were performed using R 2.14.0
(http://www.r-project.org) and STATA v10 (STATA Corp.,
College Station, TX).
Results
Frequency and distribution of genome-wide aUPD in
ovarian cancer
We analyzed SNP array-based genotyping data to deter-
mine the distribution and frequency of aUPD regions in
epithelial ovarian tumors. Our analysis yielded a total of
5,434 aUPD regions in all chromosomes for all samples
(range, 0 to 51.0 regions per sample; mean, 10.2; median,
9.0). We found that 94.7% (504/532) of ovarian cancers
harbored at least one aUPD; the most common aUPD
regions were in chromosomes 17q (76.7%; 408/532), 17p
(39.7%; 211/532), and 13q (38.3%; 204/532), indicating that
aUPD is a common event in ovarian cancer (Figure 1).
Next, we assessed whether the frequency of total
aUPD varied among tumor stages and grades. In the
Kruskal–Wallis test, the frequency of total aUPD inarian tumor samples. Each red line represents aUPD region for each
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different from that in grade 1 (p = 0.0002), [(albeit with a
very small number of grade 1 samples (6)] with the high-
est aUPD frequency in grade 3 (Figure 2A) tumors, with
similar results observed when telometric (p = 0.0009,
Figure 2B), centromeric (p = 0.0004, Figure 2C) and seg-
mental (p = 0.0002, Figure 2D) aUPD were assessed. In
contrast whole chromosome aUPD did not correlate
with grade (p = 0.8004, Figure 2E). The aUPD score
(total, telomeric, centromeric, segmental and whole
chromosome) was not significantly different among stages
(p = 0.156, p = 0.107, p = 0.144 and p = 0.118, p = 0.311,
respectively) (Additional file 5: Figure S3).
aUPD can lead to homozygosity for tumor suppressor
genes or oncogenes. To test for correlation between
homozygous mutation and aUPD regions, we integrated
the mutation status of TP53 at chromosome 17p13.1
with aUPD as TP53 is mutated with a high frequency in
high grade serous ovarian cancer. Chi-squared analysisFigure 2 Frequency of (A) total, (B) telomeric, (C) centromeric, (D) seg
1, 2, and 3 ovarian cancer.indicated that there was a statistically significant associ-
ation (p < 0.0001) between homozygous mutation of
TP53 and aUPD at chromosome 17p13.1 supporting a
role for aUPD in inactivation of this tumor suppressor
function in high grade SOC.
Recurrent aUPD regions and association with OS time and
RFS time
First, we determined the smallest overlapping regions
(SORs) in chromosomes with frequent aUPD regions:
chromosomes 17q (8 independent regions, A–H), 17p
(5 independent regions, A–E), 13q (2 independent re-
gions, A and B), 9q (2 independent regions, A and B),
and 22q (4 independent regions, A–D) (Additional file 6:
Table S3). Then, we tested whether any of these SORs
were associated with OS and/or RFS.
Univariate analysis demonstrated that two regions at
chromosome 17q (A) (24.2%) (q = 0.0009, Benjamini-
Hochberg’s FDR) (Figure 3A) and (C) (24.6%) (q = 0.03)mental, and (E) whole-chromosome aUPD in tumors with grade
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Figure 3 Overall survival and recurrence-free survival analyses. Kaplan–Meier plot of overall survival probability as a function of time for
patients with aUPD at chromosome (A) 17q A, (B) whole chromosome in all tumor samples, (C) 17q A, (D) whole chromosomes in samples set B
and (E) 17q C in all samples , and (F) whole-chromosome in sample set A. Kaplan-Meier plot of recurrence-free survival probability as a function
of time for patients with aUPD at chromosome (G) 17q A, (I) 17q D (K) BRCA1 loci in all samples, and (H) 17q A, (J) 17q D and (L) BRCA1 loci in
sample set B. Patients at risk at various time points are indicated.
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aUPD (19.9%) (q = 0.0002) (Figure 3B) were associated with
a shorter OS time (Table 1, Additional file 6: Table S3),while five regions of aUPD at 17q (A, D, E, F, G) were
associated with shorter RFS time (q = 0.03, q = 0.02,
q = 0.008, q = 0.02, q = 0.01, and q = 0.02, respectively)
Table 1 Univariate analysis of clinical and genetic factors
Variable OS
Sample set A Sample set B All samples
HR 95% CI p q HR 95% CI p q HR 95% CI p q
Age >50 vs <50 1.36 0.87-2.12 0.18 0.52 1.62 1.05-2.52 0.031 0.14 1.50 1.09-2.04 0.011 0.058
Stage, I&II vs III&IV 0.89 0.33-2.41 0.82 0.89 5.80 2.14-15.70 0.0005 0.007 3.15 1.56-6.37 0.001 0.010
Grade, 1&2 vs 3&4 1.49 0.80-2.79 0.21 0.52 1.50 0.96-2.33 0.073 0.21 1.48 1.04-2.12 0.032 0.097
Platinum status,
Resistance vs sensitive 5.28 3.23-8.64 3.41×10−11 1.26×10−9 3.29 2.07-5.22 4.28×10−7 1.58×10−5 4.02 2.90-5.57 2×10−16 2×10−16
Organ side,
Bilateral vs unilateral 1.39 0.93-2.1 0.11 0.45 0.98 0.67-1.45 0.92 0.92 1.15 0.87-1.53 0.32 0.44
aUPD regions
17q A 1.73 1.16-2.58 0.007 0.06 1.67 1.17-2.39 0.005 0.03 1.69 1.30-2.20 0.0001 0.0009
17q B 1.40 0.94-2.09 0.099 0.45 1.39 0.96-2.01 0.080 0.21 1.39 1.06-1.81 0.017 0.07
17q C 1.51 1.02-2.23 0.042 0.31 1.44 1.00-2.07 0.051 0.19 1.46 1.12-1.90 0.005 0.03
17q D 1.25 0.89-1.77 0.202 0.52 1.38 0.99-1.92 0.059 0.20 1.32 1.04-1.68 0.021 0.08
17q E 1.17 0.83-1.65 0.365 0.70 1.40 1.01-1.96 0.046 0.19 1.29 1.01-1.63 0.039 0.10
22q D 1.43 0.75-2.74 0.280 0.65 2.23 1.09-4.60 0.029 0.14 1.68 1.04-2.71 0.035 0.10
aUPD regions
PTEN 1.66 0.98-2.80 0.059 0.37 1.51 0.83-2.73 0.175 0.34 1.56 1.06-2.32 0.025 0.08
NF1 1.44 0.96-2.16 0.074 0.39 1.40 0.94-2.07 0.094 0.22 1.43 1.08-1.89 0.012 0.06
Whole chromosome
aUPD 1.80 1.23-2.65 0.003 0.03 1.89 1.27-2.81 0.002 0.01 1.83 1.39-2.41 1.59×10−5 0.0002
RFS
Age >50 vs <50 1.25 0.83-1.88 0.283 0.62 1.57 1.03-2.38 0.037 0.11 1.39 1.04-1.87 0.026 0.08
Stage, I&II vs III&IV 0.48 0.18-1.31 0.151 0.54 2.58 1.39-4.79 0.003 0.02 1.85 1.10-3.11 0.021 0.07
Grade, 1&2 vs 3&4 2.26 1.10-4.63 0.026 0.49 1.10 0.73-1.66 0.639 0.81 1.34 0.95-1.90 0.093 0.23
Platinum status,
Resistance vs sensitive 2.63 1.75-3.95 3.15×10−6 0.0001 9.04 5.76-14.17 2×10−16 2×10−16 3.84 2.88-5.13 2×10−16 2×10−16
Organ side
Bilateral vs unilateral 1.27 0.85-1.91 0.245 0.61 1.36 0.90-2.05 0.148 0.39 1.30 0.97-1.73 0.076 0.20
aUPD regions
17q A 1.26 0.84-1.90 0.263 0.61 1.68 1.15-2.44 0.007 0.03 1.47 1.11-1.93 0.007 0.03
17q B 1.60 0.77-1.75 0.482 0.78 1.73 1.18-2.52 0.005 0.02 1.41 1.07-1.87 0.014 0.06
17q C 1.14 0.75-1.72 0.535 0.78 1.73 1.18-2.52 0.005 0.02 1.41 1.06-1.86 0.016 0.06
17q D 1.34 0.95-1.89 0.098 0.54 1.55 1.11-2.17 0.010 0.04 1.45 1.14-1.84 0.003 0.02
17q E 1.33 0.94-1.88 0.106 0.54 1.77 1.26-2.49 0.0009 0.01 1.54 1.21-1.96 0.0005 0.008
17q F 1.28 0.91-1.81 0.162 0.54 1.68 1.20-2.36 0.002 0.02 1.47 1.16-1.87 0.002 0.02
17q G 1.30 0.92-1.85 0.135 0.54 1.70 1.21-2.38 0.002 0.02 1.49 1.17-1.89 0.001 0.01
17q H 1.37 0.94-1.99 0.102 0.54 1.22 0.87-1.71 0.245 0.49 1.29 1.00-1.66 0.044 0.13
aUPD regions
PTEN 1.10 0.61-1.54 0.761 0.88 1.32 0.67-2.61 0.419 0.57 1.17 0.75-1.83 0.495 0.72
NF1 1.23 0.81-1.87 0.341 0.66 1.64 1.11-2.44 0.013 0.05 1.42 1.07-1.89 0.017 0.06
BRCA1 1.13 0.76-1.67 0.548 0.78 1.97 1.36-2.84 0.0003 0.006 1.49 1.14-1.94 0.003 0.02
Whole chromosome
aUPD 1.16 0.77-1.75 0.473 0.77 1.22 0.78-1.89 .379 0.57 1.18 0.88-1.59 0.275 0.64
Abbreviation: OS overall survival, RFS recurrence free survival, aUPD acquired uniparental disomy, HR hazard ratio, q Benjamini-Hochberg’s FDR. q < 0.05 was used
to select features; bold indicates statistically significant variables.
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Additional file 7: Figure S4). As expected from previous
studies [20], univariate analysis showed that platinum
sensitivity was associated with OS and RFS (Table 1,
Additional file 7: Figure S4). However, no significant cor-
relation was found between aUPD regions and platinum
status. We also determined whether aUPD at NF1, RB1,
BRCA1, BRCA2, and PTEN, which are mutated or homo-
zygously deleted at a low prevalence in high grade SOC
[20], were associated with OS time and RFS time. Univar-
iate analysis demonstrated that aUPD at BRCA1 loci was
associated with shorter RFS time in all samples (q = 0.02)
(Figure 3K and Table 1), but not with OS time. The re-
sults of multivariate analysis showed that only aUPD at
whole chromosomes (p = 0.011) and platinum sensitivity
(p = 2.37×10−7) were significant prognostic factors con-
tributing to OS time, with platinum status (p = 2×10
−16) being a significant predictor of RFS (Table 2) in all
samples.
We split the set into two parts (Set A and Set B) to
provided independent sets for analysis. Univariate ana-
lysis demonstrated that one region at chromosome
17q (A) (q = 0.03) (Figure 3C) and samples harboringTable 2 Multivariate analysis of clinical and genetic factors
Variable HR 95% CI p
OS (all samples)
Platinum status,
Resistance vs sensitive 3.27 2.09-5.12 2.37×10−7
aUPD at
whole-chromosome 1.82 1.15-2.88 0.0108
OS (sample set A)
Platinum status,
Resistance vs sensitive 5.14 2.81-9.4 1.01×10−7
aUPD at
whole chromosome 2.17 1.29-3.66 0.0036
OS (sample set B)
Platinum status,
Resistance vs sensitive 2.48 1.12-5.47 0.0246
RFS (all samples)
Platinum status,
Resistance vs sensitive 4.16 3.07-5.64 2×10−16
RFS (sample set A)
Platinum status
Resistance vs sensitive 2.93 2.00-4.30 3.24×10−8
RFS (sample set B)
Platinum status,
Resistance vs sensitive 58.42 19.22-171.29 1.25×10−13
Abbreviation: OS overall survival, RFS recurrence free survival, aUPD acquired
uniparental disomy, HR hazard ratio, q < 0.05 was used to select features.whole-chromosome aUPD (q = 0.01) (Figure 3D) were
associated with shorter OS in the sample set B, and
only samples with whole-chromosome aUPD (q = 0.03)
(Figure 3F) were associated with shorter OS time in set A
(Table 1). In addition, aUPD in seven regions at 17q (A-G)
(q = 0.03, q = 0.02, q = 0.02, q = 0.04, q = 0.01, q = 0.02, and
q = 0.02, respectively), and aUPD at NF1 (q = 0.05), and
BRCA1 loci (q = 0.006) (Figure 3H, J and L, Table 1,
Additional file 7: Figure S4) were associated with
shorter RFS in set B, but not in set A. Univariate analysis
showed that platinum sensitivity was associated with
shorter OS in both sets A and B (q = 1.26×10−9 and
q = 1.58×10−5, respectively), and shorter RFS in both
sets (q = 0.0001 and q = 2×10−16, respectively) (Table 1,
Additional file 7: Figure S4). The results of multivariate
analysis showed that only platinum sensitivity was signifi-
cant predictor of OS time in both sets A (p = 1.01×10−7)
and B (p = 0.025), while whole-chromosome aUPD was sig-
nificant predictor of OS time in set A (p = 0.004) (Table 2),
but not in set B, with platinum status being a significant
predictor of RFS in set A (p = 3.24×10−8) and B (p =
1.25×10−13). After that analysis was performed, we also
combined set A and B to determine if with the increased
power we could identify potential predictors. However, in
the merged set, we did not have an independent test set
and all analysis should be considered exploratory.
Additional associations with aUPD regions
Chi-square analysis demonstrated that aUPD at chromo-
some 22q (B) (p = 0.0007, q = 0.02) was associated with
unilateral ovarian tumors. In addition, the frequency of
aUPD was significantly higher in ovarian cancer samples
with TP53 mutations, with aUPD at TP53, BRCA1 or
BRCA2 loci, with aUPD on 17q (A-H) or 22q (B) re-
gions (Additional file 8: Table S4 and Additional file 9:
Figure S5). In contrast, no association was found between
the frequency of aUPD and mutation of other genes pro-
posed to contribute to homologous recombination or
double-strand break repair (Additional file 8: Table S4).
Of the 8 regions associated with outcomes or clinical
characteristics, four in chromosome 17q (A–D) and one
region in chromosome 22q (B) harbor open reading
frames for known proteins. Reminiscent of a number of
sites identified in genome-wide association studies, the
remaining 3 regions in 17q (E–G) do not harbor open
reading frames for proteins (Table 3). When we inte-
grated mutation data from the TCGA database [20] for
genes known to be mutated in ovarian cancer, from the
74 genes located within the SOR aUPD regions associated
with outcomes, 33 genes were mutated either homozy-
gously or heterozygously, and 6 genes were mutated homo-
zygously in at least one patient in the TCGA ovarian
cancer database [20] (Table 3) (p = 0.462). Genes or poten-
tially miRNA or noncoding RNA in SOR aUPD regions
Table 3 Genes in the small overlapping regions of aUPD in chromosomes 17q, and 22q that correlate with OS and/or
RFS time or anatomic side
Chromosomal region Chromosomal position Start-end position Genes
17q A 17q12-q21.2 35.139.198-35.611.217 GRB7, IKZF3, ZPBP2, GSDMB, ORMDL3, LRRC3C, GSDMA, PSMD3, CSF3,
MED24, THRA, NR1D1, MSL1, CASC3, RAPGEFL1
17q B 17q21.2 37.079.721-37.604.187 EIF1, HAP1, GAST, JUP, LEPREL4, NT5C3L, FKBP10, KLHL10, KLHL11, ACLY,
TTC25, CNP, DNAJC7, NKIRAS2, ZNF385C, DHX58, KAT2A, HSPB9, RAB5C,
KCNH4, HCRT, GHDC
17q C 17q21.2 37.244.697-37.559.796 NT5C3L, FKBP10, KLHL10, KLHL11, ACLY, TTC25, CNP, DNAJC7, NKIRAS2,
ZNF385C, DHX58, KAT2A, HSPB9, RAB5C
17q D 17q21.33 45.311.230-45.815.839 DLX4, DLX3, LOC284080, ITGA3, PDK2, PPP1R9B, SGCA, HILS1, COL1A1,
TMEM92, XYLT2, MRPL27, EME1, LRRC59
17q E 17q22 48.041.053-43.303.286 No gene
17q F 17q22 49.352.217-49.666.897 No gene
17q G 17q22 49.771.790-50.243.809 No gene
22q B 22q11.2 29.263.787-29.738.848 SEC14L6, GAL3ST1, PES1, SLC35E4, TCN2, DUSP18, OSBP2, MORC2, TUG1
Bold indicates genes that mutated. aUPD, acquired uniparental disomy; OS, overall survival.
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methylation or histone modification.
Discussion
In this study, we have determined the distribution and
frequency of aUPD regions in ovarian cancer and inves-
tigated the association of aUPD with RFS time and OS
time. aUPD regions were found in all chromosomes,
with the most frequent aUPD at chromosome 17q
(76.7% of SOC samples). Pederson et al. found an in-
crease in copy-neutral LOH in association with age [24].
The frequency of centromeric, telomeric, and segmental
aUPD was higher in grades 2 and 3 than that in grade 1
SOC, consistent with previous studies indicating that
grade 2 and 3 serous tumors arise from different mo-
lecular pathways [6-9].
The association between aUPD at the TP53 region and
homozygous mutation of TP53 supports the contention
that aUPD can lead to inactivation of the function of im-
portant tumor suppressor genes in SOC. Tumors har-
boring aUPD at TP53, 17q A-H, or 22q B and D regions
were associated with a higher frequency of total aUPD
events suggesting that TP53 as well as genes in the 17q
and 22q regions may contribute or select for aUPD.
Two regions at chromosome 17q (A and C) and
whole-chromosome aUPD were associated with shorter
OS time, and five regions of aUPD at 17q (A, D-G) and
the BRCA1 loci were associated with shorter RFS time
in all samples (Figure 3). Previous studies showed that
altered expression and copy number of genes and/or
miRNAs [20,25-27] were associated with outcome of
disease dependent on mechanisms of inactivation or ac-
tivation of genes [20]. For instance, BRCA1/2 mutated
cases have been reported to be associated with improved
OS compared to BRCA1/2 wild-type, whereas methyl-
ated BRCA1 cases had similar OS time to BRCA1/2wild-type cases [20]. On the other hand, LOH analysis of
epithelial ovarian cancer has shown that LOH at
22q13.31-q13.33 predicts prolonged progression free
survival (p = 0.03), that was not statistically significant in
adjusted (for stage, optimal cytoreduction, and germline
BRCA mutation status) analysis (q = 0.2) [13]. In addition,
LOH profiling of high-grade serous ovarian cancer, sepa-
rated into copy loss (hemizygosity), or copy neutral loss of
one allele (homozygosity), and frequency of LOH demon-
strated three subclusters (HiA, HiB and Lo) based on dis-
tribution and frequency of LOH. These three clusters
were found to differ in response to chemotherapy, with
the highest chemotherapy-resistance rate in the Lo-
subcluster, and a longer median progression-free survival
in HiA-subcluster [28]. LOH may pinpoint hemizygous or
homozygous regions in the tumor genome, which often
exhibit loss-of-function mutations; in contrast, aUPD pin-
points only homozygous regions, which renders both loss-
of-function and gain-of-function mutations homozygous.
Allele based analysis is required to distinguish between
LOH and aUPD events [19,29]. Our results add novel
findings to previous reports on the clinical significance of
chromosomal instability in ovarian cancer: not only do
chromosomal instability, LOH and gene expression pro-
files correlate with ovarian cancer outcome [20,25-27] but
aUPD has prognostic significance in this disease.
Only aUPD at chromosome 17q was associated with
shorter OS and RFS time in all samples and sample set
B, and whole-chromosome aUPD was associated with
shorter OS in all samples and in independent analysis of
sets A and B. Thus whole-chromosome aUPD appears
to be a prognostic factor in serous epithelial ovarian can-
cer. This led us to hypothesize that the aUPD regions
in chromosome 17q harbor genes homozygous for exist-
ing abnormalities such as gain-of-function or loss-of-
function mutation, methylation, histone modification, or
Tuna et al. Molecular Cancer  (2015) 14:29 Page9of10imprinting. Indeed multiple cancer associated genes as
well as genes reported to be mutated in ovarian cancers
are located within these regions. Of the candidate genes
in the regions, the product of GRB7 is an adapter pro-
tein that interacts with many receptor tyrosine kinases,
including the epidermal growth factor receptor (EGFR),
human EGFR receptor 2 (HER2), and ephrin receptors
[30]. GRB7 also plays a crucial role in the integrin sig-
naling pathways. GRB7 is overexpressed in ovarian can-
cer cells and promotes cell proliferation, migration, and
invasion in high grade ovarian cancer [31]. CARD10
(also known as CARMA3) mediates activation of NF-κB
and tumor progression [32]. Methylation of JUP, also
known as gamma-catenin, correlates with poor progno-
sis in renal cell carcinoma [33]. Gamma-catenin sensi-
tizes cells to platinum compounds with reduced levels of
gamma-catenin contributing to cisplatin resistance [34].
KAT2A (also known as GCN5 histone acetyltransferase)
controls glucose metabolism [35] and regulates cell
cycle-related genes and apoptosis-related genes via his-
tone modification [36]. ACLY (ATP citrate lyase) is a
crucial gene in the lipogenic pathway that is overex-
pressed in serous ovarian cancer [37]. Inhibition of
ACLY suppresses the AKT signaling pathway which is
important in ovarian cancer [38].
In conclusion, the results of this study provide new in-
sights into the role of aUPD in epithelial ovarian tumori-
genesis and indicate that aUPD has prognostic relevance
in this disease. Further functional studies on candidate
genes in aUPD regions that have prognostic relevance
will be required to elucidate their potential relevance in
the pathophysiology and in treatment efficacy of ovarian
cancer.
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Kaplan–Meier plot of recurrence free survival probability as a function of
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17q G in all samples. Kaplan–Meier plot of recurrence free survival
probability as a function of time for patients with platinum status in (J)
set A, (K) set B, and (L) all samples. Kaplan–Meier plot of overall survival
probability as a function of time for patients with platinum status in (M)
set A, (N) set B, and (O) all samples. Kaplan–Meier plot of overall survival
probability as a function of time for patients with response to therapy in
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(A-D), TP53, BRCA1 and BRCA2.
Additional file 9: Figure S5. Association between frequency of aUPD
and somatic mutation at TP53, at BRCA1 and BRCA2, and aUPD at TP53,
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